1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H1 2020, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape.
Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 18, 18, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Gastrointestinal Stromal Tumor - Overview
- Gastrointestinal Stromal Tumor - Therapeutics Development
- Gastrointestinal Stromal Tumor - Therapeutics Assessment
- Gastrointestinal Stromal Tumor - Companies Involved in Therapeutics Development
- Gastrointestinal Stromal Tumor - Drug Profiles
- Gastrointestinal Stromal Tumor - Dormant Projects
- Gastrointestinal Stromal Tumor - Discontinued Products
- Gastrointestinal Stromal Tumor - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by ABL Bio Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group International, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eisai Co Ltd, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Esperas Pharma Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- ABL Bio Inc
- Advenchen Laboratories LLC
- Arog Pharmaceuticals Inc
- Ascentage Pharma Group International
- Bayer AG
- Blueprint Medicines Corp
- Calithera Biosciences Inc
- Chipscreen Biosciences Ltd
- CStone Pharmaceuticals Co Ltd
- Daiichi Sankyo Co Ltd
- Deciphera Pharmaceuticals Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Esperas Pharma Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Hanmi Pharmaceuticals Co Ltd
- Hefei Cosource Pharmaceutical Inc
- Horizon Therapeutics Plc
- Immunicum AB
- ImmunityBio Inc
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Karyopharm Therapeutics Inc
- Marino Biotechnology Co Ltd
- Merck & Co Inc
- Merck KGaA
- Ningbo Tai Kang Medical Technology Co Ltd
- NMS Group SpA
- Novartis AG
- Omeros Corp
- Pfizer Inc
- Pharma Mar SA
- Plexxikon Inc
- Rhizen Pharmaceuticals SA
- Sartar Therapeutics Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Soricimed Biopharma Inc
- Taiho Oncology Inc
- Takeda Pharmaceutical Co Ltd
- Xencor Inc
